Biocon’s subsidiary -- Biocon Biologics has entered into settlement agreement with Amgen Inc. that clears the path for the commercialization of its Denosumab biosimilars in Europe and the rest of the world (ROW). The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025. The other terms of the settlement remain confidential.
The European Commission (EC) had approved Vevzuo and Evfraxy in July 2025. Biocon Biologics had secured a market entry date for its Denosumab biosimilars Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) for the United States previously.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
